.
MergerLinks Header Logo

New Deal


Announced

Completed

Ekuinas completed the acquisition of a 80% stake in Symbiotica.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For80%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Malaysia

pharmaceuticals

Pharmaceuticals

Acquisition

Domestic

Single Bidder

Private

Majority

Private Equity

Completed

Friendly

Synopsis

Edit

Ekuinas, a private equity fund management company, completed the acquisition of a 80% stake in Symbiotica, a pharma ingredients producer. Financial terms were not disclosed. “Having achieved progressive and consistent growth over the past two decades, and being a well-regulated and certified API supplier, Symbiotica, as one of the largest API manufacturers in SEA, is well-positioned to take advantage of the macro trends driving this sector’s future growth," Datuk Syed Yasir Arafat Syed Abd Kadir, Ekuinas CEO.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US